A case of recurrent colon cancer with angina pectoris and interstitial pneumonia during cetuximab therapy with death by carcinomatous lymphangiosis

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 11, 2010, Pages 2193-2198

  Shibahara, Hiroaki ^a,b   Kuze, Shingo ^a   Kyokane, Takanori ^a   Takamizawa, Junichi ^a   Nakamura, Hayato ^a   Morikawa, Syuji ^a   Hayashi, Eijiro ^a   Kinoshita, Mana ^c   Baba, Satoshi ^c  

^a Fukuroi Municipal Hospital   (Japan)

^b Department of Clinical Laboratory   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angina pectoris; Cetuximab; Interstitial pneumonia

Indexed keywords

CETUXIMAB; STEROID; VASODILATOR AGENT;

ADULT; ANGINA PECTORIS; ARTICLE; ASSISTED VENTILATION; AUTOPSY; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOMATOSIS; CARCINOMATOUS LYMPHANGIOSIS; CASE REPORT; CAUSE OF DEATH; CHEST TIGHTNESS; COLON CANCER; DRUG FEVER; DRUG PULSE THERAPY; DYSPNEA; FEVER; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; LUNG METASTASIS; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; RECURRENT CANCER; RESPIRATORY FAILURE; STEROID THERAPY; VASOSPASM; VASOSPASTIC ANGINA;

EID: 79961176132     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7): 1201-1208, 2004. (Pubitemid 41079832)
2. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4): 337-345, 2004. (Pubitemid 38944402)
3. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20): 2040-2048, 2007. (Pubitemid 350106711)
4. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14): 1408-1417, 2009.
5. Burgess AW: EGFR family. Structure physiology signalling and therapeutic targets. Growth Factors 26(5): 263-274, 2008.
6. De Luca A, Carotenuto A, Rachiglio A, et al: The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214(3): 559-567, 2008. (Pubitemid 351224199)
7. Iwamoto R and Mekada E: ErbB and HB-EGF signaling in heart development and function. Cell Struct Funct 31 (1): 1-14, 2006.
8. Fuller SJ, Sivarajah K and Sugden PH: ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol 44 (5): 831-854, 2008.
9. Keefe DL: Trastuzumab-associated cardiotoxicity. Cancer 95(7): 1592-1600, 2002.
10. Routledge HC, Rea DW and Steeds RP: Monitoring the introduction of new drugs - Herceptin to cardiotoxicity. Clin Med 6(5): 478-481, 2006. (Pubitemid 44690284)
11. Ewer MS and Lippman SM: Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23(13): 2900-2902, 2005. (Pubitemid 46224107)
12. Pentassuglia L, Graf M, Lane H, et al: Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res 315(7): 1302-1312, 2009.
13. Chua W, Peters M, Loneragan R, et al: Cetuximab-associated pulmonary toxicity. Clin Colorectal Cancer 8(2): 118-120, 2009.